Paraxel joins hands with ASAN Medical Centre and increases presence in Asia

In Clinical Trials by Simon Crompton-ReidLeave a Comment

Seoul based ASAN Medical Centre (AMC) and Paraxel International (#Paraxel) form an alliance to offer study sponsors, a gateway to clinical trial (#Pharma) (#trials) services, in Korea and across Asia. The alliance will aim for early development, where Parexel already provides access to patients in key therapeutic areas through its early-phase units and global alliance network.

With this tie up, Paraxel increases its capabilities into Asia. The AMC consists of a medical complex and large hospital with a strong record of clinical research in areas such as cancer, ischaemic diseases and chronic respiratory conditions.

The AMC Clinical Trial Centre opened in 2002 to support trials conducted by the ASAN Medical Centre. It was designated a Regional Clinical Trial Centre by the Korean Ministry for Health, Welfare, and Family Affairs in 2006.

With ASAN Medical Centre's leadership in clinical trials, in-depth expertise, state-of-the art facilities and a renowned network of hospitals, Paraxel believes their alliance will offer unique advantages to the Korean biopharmaceutical industry.

AMC is looking forward to collaborating with Parexel through their Department of Clinical Pharmacology and Therapeutics to promote, facilitate and enhance the development and use of novel pharmacotherapeutics.

Parexel has been operating in the Asia/Pacific region for over 16 years now. The company fields more than 2,800 employees and 21 offices in countries including Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan and Thailand.

Jeffrey Kasher, VP & COO, Global Clinical Development, Eli Lilly, USA will be presenting at Pharma Trials World Asia 2012 this March on "Forging open partnerships between Pharmas & Biotechs to foster increased innovation in Asian clinical Development."

Click here to register your attendance at this conference now.

Leave a Comment

Current ye@r *